Cell Therapeutics (CTIC) Posts Q3 Loss of 16c/Share; Resubmits Pixantrone NDA to FDA
Tweet
Share
E-mailGet Alerts CTIC Hot Sheet
Join SI Premium – FREE
Cell Therapeutics Inc. (NASDAQ: CTIC) reported Q3 loss of ($0.16), $0.07 worse than the analyst estimate of ($0.09).
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.
Cell Therapeutics also resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma for patients who have failed two or more prior lines of therapy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Natural Gas Inventory 36 bcf vs 31 bcf Expected
- SVB & T Corporation (SVBT) Tops Q2 EPS by 275c
- Newton Golf Company (NWTG) Reports Q2 Loss of $0.49
Create E-mail Alert Related Categories
Commodities, Earnings, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
